Journal of Diabetes Research / 2019 / Article / Tab 1

Review Article

Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential

Table 1

Overview of preclinical trials assessing the efficacy of Tie2 signalling for the treatment of DR.

ReferenceTherapyTherapeutic mechanismAnimal modelInhibited angiogenesis?Inhibited vasopermeability?Comments

Joussen et al. [65]IVT rAng1, Ad-Ang1Upregulated Tie2 phosphorylationSTZ mousen/aYesAlso showed Ang1 protects against leukocyte-mediated EC damage
Nambu et al. [63]Overexpression of Ang1 using transgenic modelUpregulated Tie2 phosphorylationOIR mouse, laser-induced NV mouseYesYes
Nambu et al. [64]Overexpression of Ang1 using transgenic modelUpregulated Tie2 phosphorylationOIR mouse, laser-induced NV mouseNon/aPrevented retinal detachment
Lee et al. [50]IVT of rAng1β5 integrin signallingOIR mouseYesYesAlso shown to be effective in ROP
Shen et al. [68]IVT of anti-Ang2 antibodyUpregulated Tie2 phosphorylationOIR mouseYesYes
Cahoon et al. [66]AAV2.COMP-Ang1Upregulated Tie2 phosphorylationInsIIAkita transgenic mousen/aYesAlso restored retinal neurophysiological responses

IVT = intravitreal injection; OIR = oxygen-induced retinopathy; STZ = streptozotocin; EC = endothelial cell; NV = neovascularisation; ROP = retinopathy of prematurity; InsIIAkita = mouse model of diabetes with mutated insulin II gene.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.